Fischer Medical Ventures Limited has informed the Exchange regarding Board meeting held on August 14, 2025.
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures' Board met on August 14, 2025 and approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) along with a limited review report from Bilimoria Mehta & Co. with an unmodified opinion. On a standalone basis, revenue from operations fell to Rs 454.23 lakhs (from Rs 521.97 lakhs YoY) and the company reported a net loss of Rs 60.94 lakhs, narrower than the Rs 89.05 lakh loss a year ago. On a consolidated basis, revenue dropped sharply to Rs 1,152.83 lakhs (from Rs 2,098.13 lakhs YoY) with net profit at Rs 40.28 lakhs versus Rs 183.78 lakhs last year. The Board fixed the 32nd AGM for September 29, 2025 via video conferencing, approved closure of the register of members from September 23-29, 2025, and recommended appointing Nuren Lodaya & Associates as Secretarial Auditors for five years. It also noted the resignation of Independent Director Dr. Jacob Thomas (DIN: 10639814) effective close of business on August 14, 2025, citing personal reasons.
The sharp year-on-year decline in consolidated revenue and profit is a negative signal for investors, though standalone losses have narrowed. The exit of an independent director and the AGM/book closure window (Sept 23-29) are routine governance items and not expected to move the stock materially on their own.